Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 4
2004 2
2005 10
2006 5
2007 3
2008 16
2009 17
2010 15
2011 15
2012 33
2013 35
2014 47
2015 60
2016 68
2017 78
2018 72
2019 91
2020 56
Text availability
Article attribute
Article type
Publication date

Search Results

558 results
Results by year
Filters applied: . Clear all
Page 1
Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke.
Wang S, Ma F, Huang L, Zhang Y, Peng Y, Xing C, Feng Y, Wang X, Peng Y. Wang S, et al. Among authors: Ma F. CNS Neurol Disord Drug Targets. 2018;17(5):338-347. doi: 10.2174/1871527317666180612125843. CNS Neurol Disord Drug Targets. 2018. PMID: 29895257 Review.
Ubiquitination of UVRAG by SMURF1 promotes autophagosome maturation and inhibits hepatocellular carcinoma growth.
Feng X, Jia Y, Zhang Y, Ma F, Zhu Y, Hong X, Zhou Q, He R, Zhang H, Jin J, Piao D, Huang H, Li Q, Qiu X, Zhang Z. Feng X, et al. Among authors: Ma F. Autophagy. 2019 Jul;15(7):1130-1149. doi: 10.1080/15548627.2019.1570063. Epub 2019 Jan 27. Autophagy. 2019. PMID: 30686098 Free PMC article.
Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis.
Han Y, Wang J, Liu W, Yuan P, Li Q, Zhang P, Ma F, Luo Y, Fan Y, Chen S, Cai R, Li Q, Xu B. Han Y, et al. Among authors: Ma F. Cancer Manag Res. 2019 May 23;11:4699-4706. doi: 10.2147/CMAR.S198962. eCollection 2019. Cancer Manag Res. 2019. PMID: 31213894 Free PMC article. Review.
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Ma F, Ouyang Q, Li W, Jiang Z, Tong Z, Liu Y, Li H, Yu S, Feng J, Wang S, Hu X, Zou J, Zhu X, Xu B. Ma F, et al. J Clin Oncol. 2019 Oct 10;37(29):2610-2619. doi: 10.1200/JCO.19.00108. Epub 2019 Aug 20. J Clin Oncol. 2019. PMID: 31430226
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J, Luo Y, Xing P, Lan B, Li M, Yi Z, Cai R, Yuan P, Zhang P, Li Q, Xu B. Ma F, et al. J Clin Oncol. 2017 Sep 20;35(27):3105-3112. doi: 10.1200/JCO.2016.69.6179. Epub 2017 May 12. J Clin Oncol. 2017. PMID: 28498781 Clinical Trial.
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
Ma F, Zhu Y, Liu X, Zhou Q, Hong X, Qu C, Feng X, Zhang Y, Ding Q, Zhao J, Hou J, Zhong M, Zhuo H, Zhong L, Ye Z, Xie W, Liu Y, Xiong Y, Chen H, Piao D, Sun B, Gao Z, Li Q, Zhang Z, Qiu X, Zhang Z. Ma F, et al. Hepatology. 2019 Nov;70(5):1785-1803. doi: 10.1002/hep.30703. Epub 2019 Jun 21. Hepatology. 2019. PMID: 31066068
558 results
Jump to page
Feedback